Piramal Pharma Solutions upgrades Pithampur site
The site has been successfully inspected by a host of regulatory agencies including FDA (US), MHRA (UK), MPA (Sweden), TGA (Australia), FIMEA (Finland) and ANVISA (Brazil).
Mumbai: Piramal Pharma Limited's Pharma Solutions business, a Contract Development and Manufacturing Organization (CDMO), has announced a new production block has come online at the company's drug product site in Pithampur, in the state of Madhya Pradesh, India.
The new production area, known as V Block, can handle batch sizes of 150 to 600 kilograms, augmenting the site's capacity to produce oral solid dosage form drug product. With the addition of V Block, the Pithampur site's total production capacity increases from 3 billion doses to 4.5 billion doses. V Block includes aqueous and non-aqueous wet granulation (high shear, top spray and bottom spray); direct, mono, and bilayer compression; aqueous and non-aqueous coating; and bottle packaging technologies.
"Aggregation capabilities related to USFDA e-pedigree and track and trace requirements are planned for V Block, as is the addition of dry granulation capabilities (roller compaction). Like the other four production blocks on site, V Block has dedicated personnel and material entry with biometric access control for the block and the operating cubicles within it, as well as dedicated air handling unit for each cubicle," the company stated.
Read also: Piramal Pharma signs Amyra Dastur as brand ambassador for Lacto Calamine skin care product range
Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions, said, "The launch of this new large-scale production block represents a significant expansion of our ability to supply oral solid dosage form drug product to customers around the world. This additional capacity further reiterates our commitment to being a patient-centric organization that's focused on helping clients reduce the burden of disease on patients."
The site has been successfully inspected by a host of regulatory agencies including FDA (US), MHRA (UK), MPA (Sweden), TGA (Australia), FIMEA (Finland) and ANVISA (Brazil).
Read also: Piramal Pharma Solutions new API Plant in Canada goes online
